Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$49.38 - $63.75 $86,810 - $112,072
1,758 Added 24.76%
8,858 $551,000
Q3 2023

Nov 13, 2023

SELL
$48.64 - $62.51 $123,059 - $158,150
-2,530 Reduced 26.27%
7,100 $398,000
Q2 2023

Aug 11, 2023

SELL
$47.99 - $60.21 $129,573 - $162,567
-2,700 Reduced 21.9%
9,630 $486,000
Q1 2023

May 11, 2023

SELL
$52.6 - $67.34 $114,352 - $146,397
-2,174 Reduced 14.99%
12,330 $672,000
Q4 2022

Feb 13, 2023

BUY
$59.56 - $76.6 $863,858 - $1.11 Million
14,504 New
14,504 $906,000
Q2 2022

Aug 12, 2022

SELL
$39.5 - $64.42 $7.27 Million - $11.8 Million
-183,928 Reduced 74.53%
62,844 $3.56 Million
Q1 2022

May 13, 2022

BUY
$43.74 - $62.76 $2.45 Million - $3.51 Million
55,998 Added 29.35%
246,772 $15.4 Million
Q4 2021

Feb 11, 2022

SELL
$50.01 - $73.35 $9.7 Million - $14.2 Million
-193,926 Reduced 50.41%
190,774 $10.7 Million
Q3 2021

Nov 10, 2021

BUY
$59.21 - $78.66 $652,198 - $866,439
11,015 Added 2.95%
384,700 $25 Million
Q2 2021

Aug 16, 2021

SELL
$51.39 - $66.9 $179,865 - $234,150
-3,500 Reduced 0.93%
373,685 $23.7 Million
Q1 2021

May 13, 2021

BUY
$49.14 - $59.89 $7.94 Million - $9.67 Million
161,490 Added 74.87%
377,185 $22.6 Million
Q4 2020

Feb 16, 2021

BUY
$42.19 - $51.5 $2.15 Million - $2.62 Million
50,955 Added 30.93%
215,695 $10.8 Million
Q3 2020

Nov 13, 2020

BUY
$35.33 - $51.04 $194,279 - $280,668
5,499 Added 3.45%
164,740 $8.41 Million
Q2 2020

Aug 14, 2020

SELL
$22.91 - $39.83 $1.93 Million - $3.36 Million
-84,408 Reduced 34.64%
159,241 $5.59 Million
Q1 2020

May 14, 2020

BUY
$16.44 - $37.73 $1.45 Million - $3.34 Million
88,435 Added 56.98%
243,649 $6.19 Million
Q4 2019

Feb 13, 2020

BUY
$19.57 - $28.96 $3.04 Million - $4.49 Million
155,214 New
155,214 $4.3 Million

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.49B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.